Form 8-K - Current report:
SEC Accession No. 0001193125-25-004062
Filing Date
2025-01-10
Accepted
2025-01-10 07:00:18
Documents
14
Period of Report
2025-01-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d925391d8k.htm   iXBRL 8-K 34279
2 EX-99.1 d925391dex991.htm EX-99.1 22057
  Complete submission text file 0001193125-25-004062.txt   186459

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20250109.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20250109_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20250109_pre.xml EX-101.PRE 10824
16 EXTRACTED XBRL INSTANCE DOCUMENT d925391d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 25520338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)